OBJECTIVE: The aim of this study was to investigate the efficacy and safety of dual antiplatelet drugs combined with different doses of tirofiban on diabetic patients with acute myocardial infarction (AMI) receiving emergency percutaneous coronary intervention (PCI). METHODS:158 diabetic patients with AMI undergone emergency PCI were randomly divided into three groups: Group A (53 cases) as the control group-dual anti-platelet agents (aspirin + ticagrelor); Group B (52 cases)-dual anti-platelet agents + conventional dose of tirofiban [10 μg/kg by PCI and 0.15 μg/(kg·min) by continue venous pump for 24 h]; Group C (53 cases)-dual antiplatelet agents + half-dose tirofiban [10 μg/kg by PCI and 0.075 μg/(kg·min) by continue venous pump for 24 h]. RESULTS: Compared with group A, thrombolysis in myocardial infarction 3 (TIMI3) blood flow and TIMI myocardial perfusion grade 3 (TMPG3) myocardial perfusion of patients in group B and group C after PCI was significantly higher (P < 0.05), the average day of hospitalization was significantly shorter (P < 0.05), reinfarction during hospitalization, post-infarction angina, severe arrhythmia, the incidence of cardiac function above KillipIII level was significantly lower (P < 0.05). And the differences between group B and C was not statistically significant (P > 0.05). Severe bleeding and moderate incidence of bleeding in group B was significantly higher than that in group A and group C (P < 0.05). CONCLUSIONS: Based on combination of dual the anti-platelet agents and ticagrelor for diabetic patients with AMI receiving PCI, the combination of half-dose tirofiban can effectively improve TIMI flow and TMPG myocardial tissue perfusion, and reduce the incidence of major adverse cardiac events (MACE) and severe bleeding.
RCT Entities:
OBJECTIVE: The aim of this study was to investigate the efficacy and safety of dual antiplatelet drugs combined with different doses of tirofiban on diabeticpatients with acute myocardial infarction (AMI) receiving emergency percutaneous coronary intervention (PCI). METHODS: 158 diabeticpatients with AMI undergone emergency PCI were randomly divided into three groups: Group A (53 cases) as the control group-dual anti-platelet agents (aspirin + ticagrelor); Group B (52 cases)-dual anti-platelet agents + conventional dose of tirofiban [10 μg/kg by PCI and 0.15 μg/(kg·min) by continue venous pump for 24 h]; Group C (53 cases)-dual antiplatelet agents + half-dose tirofiban [10 μg/kg by PCI and 0.075 μg/(kg·min) by continue venous pump for 24 h]. RESULTS: Compared with group A, thrombolysis in myocardial infarction 3 (TIMI3) blood flow and TIMI myocardial perfusion grade 3 (TMPG3) myocardial perfusion of patients in group B and group C after PCI was significantly higher (P < 0.05), the average day of hospitalization was significantly shorter (P < 0.05), reinfarction during hospitalization, post-infarction angina, severe arrhythmia, the incidence of cardiac function above KillipIII level was significantly lower (P < 0.05). And the differences between group B and C was not statistically significant (P > 0.05). Severe bleeding and moderate incidence of bleeding in group B was significantly higher than that in group A and group C (P < 0.05). CONCLUSIONS: Based on combination of dual the anti-platelet agents and ticagrelor for diabeticpatients with AMI receiving PCI, the combination of half-dose tirofiban can effectively improve TIMI flow and TMPG myocardial tissue perfusion, and reduce the incidence of major adverse cardiac events (MACE) and severe bleeding.
Authors: Deepak L Bhatt; Michel E Bertrand; Peter B Berger; Philippe L L'Allier; Issam Moussa; Jeffrey W Moses; George Dangas; Megumi Taniuchi; John M Lasala; David R Holmes; Stephen G Ellis; Eric J Topol Journal: J Am Coll Cardiol Date: 2002-01-02 Impact factor: 24.094
Authors: Frederick G Kushner; Mary Hand; Sidney C Smith; Spencer B King; Jeffrey L Anderson; Elliott M Antman; Steven R Bailey; Eric R Bates; James C Blankenship; Donald E Casey; Lee A Green; Judith S Hochman; Alice K Jacobs; Harlan M Krumholz; Douglass A Morrison; Joseph P Ornato; David L Pearle; Eric D Peterson; Michael A Sloan; Patrick L Whitlow; David O Williams Journal: Circulation Date: 2009-11-18 Impact factor: 29.690
Authors: Yahya B Juwana; Harry Suryapranata; Jan Paul Ottervanger; Arnoud W J van 't Hof Journal: Expert Opin Pharmacother Date: 2010-04 Impact factor: 3.889
Authors: Tobias Geisler; Meinrad Gawaz; Steven R Steinhubl; Deepak L Bhatt; Robert F Storey; Marcus Flather Journal: Pharmacol Ther Date: 2010-06-01 Impact factor: 12.310
Authors: Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Jaroslaw Zalewski; Krzysztof Nycz; Tadeusz Przewlocki; Monika Durak; Michal Cul; Wojciech Zajdel; Krzysztof Zmudka Journal: Int J Cardiol Date: 2009-08-25 Impact factor: 4.164